CAR therapy
CAR T-Cell Therapy Approved for Heavily Pretreated Multiple Myeloma
The FDA approved the chimeric antigen receptor T-cell therapy ciltacabtagene autoleucel, or cilta-cel, (Carvykti, ...
MARCH 1, 2022
CAR T-Cell Therapy Extends Survival in Relapsed/Refractory Mantle Cell Lymphoma
ORLANDO, FLA.—In patients with relapsed or refractory mantle cell lymphoma and few remaining treatment ...
FEBRUARY 25, 2020
Novel Agent Found Effective in B-Cell Cancers, Even After CAR T-Cell Failure
A novel investigational bispecific antibody therapy called mosunetuzumab produced durable complete response sin ...
FEBRUARY 24, 2020
Combo Rx Boosts Durability of CAR T-Cell Response
In hematologic malignancies, chimeric antigen receptor-modified T cells will be increasingly combined with other ...
APRIL 3, 2019
Immunotherapy Can Stall Without Supportive Care
Anaheim, Calif.—A young man came to Memorial Sloan Kettering Cancer Center (MSK) looking for help. He had ...
MARCH 7, 2019
ALL Has Potential to Relapse After CAR T-Cell Therapy
B-cell acute lymphoblastic leukemia can recur when leukemic cells become resistant to chimeric antigen receptor ...
OCTOBER 26, 2018
FDA Approves CAR Therapy Yescarta To Treat Large B-Cell Lymphomas
Axicabtagene ciloleucel (Yescarta, Kite Pharma) has been approved to treat adults with relapsed or refractory ...
OCTOBER 24, 2017
CAR-T Therapy Kymriah Granted FDA Approval
The FDA has approved the first CAR-T therapy, tisagenlecleucel (Kymriah, Novartis), for the treatment of patients ...
AUGUST 31, 2017
CAR Therapy Research Heats Up
Boston—While checkpoint inhibitors may be stealing the cancer news spotlight these days, advances in chimeric ...
APRIL 18, 2017
Immunotherapies for CLL Complement Targeted Agents
In CLL, the activity of immunotherapies may be enhanced when they are administered in combination with ibrutinib ...
MARCH 23, 2017
